Updated:
Generex Biotechnology
Generex Biotechnology is a Toronto-based biotech firm known for its oral insulin spray Oral-lyn, focused on diabetes and drug delivery.
Generex Biotechnology
Generex Biotechnology is a healthcare holding company based in Miramar, Florida. It focuses on patient-centric care across immune-oncology, medical devices, and diagnostics. The company offers end-to-end solutions through a management services organization and a network of pharmacies, a clinical laboratory, and medical device companies.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
Toronto
Corporate office
Toronto, ON, Canada
Sector focus
Frequently asked questions
Who controls Generex Biotechnology?
Generex Biotechnology is a publicly traded company (OTC: GNBT), meaning its governance is through a board of directors rather than a single controlling entity. No named individuals or family offices have been publicly disclosed as principal owners or managers (per public SEC filings).
What is Generex's primary product and development status?
Generex's most recognized product is Oral-lyn, an oral insulin spray for diabetes management. As of public sources, the product has not received FDA approval and its clinical trial results have been reported but not sufficient for commercialization (per the firm's own communications).
Does Generex have partnerships or external investors?
Public records do not identify any institutional allocators, family offices, or major strategic partners with disclosed commitments. The company has historically raised funds through public equity offerings and at-the-market offerings (per SEC filings).
How does Generex compare to other oral insulin developers?
Generex is one of several firms attempting non-invasive insulin delivery, alongside companies like Novo Nordisk (oral semaglutide) and Oramed Pharmaceuticals. Generex uses a buccal spray technology distinct from Oramed's oral capsule approach, but has not achieved late-stage regulatory milestones (per industry reports).
Is Generex Biotechnology a family office or asset manager?
No. Generex Biotechnology is a publicly traded biotechnology company, not a family office or asset manager. It does not manage third-party capital nor operate as an investment vehicle for a family (per its corporate filings).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: